Viewing nowJardiance 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

MFDS item code 202102269 · Approved 2021.03.12 · Insurance code 644915030
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in combination with diet and exercise to help adults with type 2 diabetes control their blood sugar. It can be administered as monotherapy, and in cases where blood sugar control is difficult, it may be used in combination with metformin, pioglitazone, sulfonylureas, insulin, or the DPP-4 inhibitor linagliptin. It should be used cautiously in patients with type 2 diabetes and cardiovascular disease, and relevant clinical trial information should be referenced. This medication is effective for improving the patient's blood sugar control and is used effectively in diabetes treatment.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If additional glycemic control is needed and 10 mg of this medicine is well tolerated, the dose may be increased to 25 mg once daily. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you forget to take this medicine, take it as soon as you remember. Do not take double the dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent eGFR below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the eGFR decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in older adults aged 85 years and older due to limited clinical experience (see Precautions for Use, section 4, General Precautions).
This medication should be avoided in certain patients. First, individuals with allergies to the active ingredient or any component of this medication should not use it. Second, it should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Third, patients with severely impaired kidney function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m2 or those on dialysis due to end-stage renal disease, should not take this medication. Fourth, since it contains lactose, patients with genetic metabolic disorders such as lactose intolerance or galactose intolerance should also avoid this medication. Caution is needed when administering this medication to patients with slightly impaired kidney function. It is advisable not to initiate treatment with this medication in patients with a glomerular filtration rate of less than 60 mL/min/1.73m2, and doses may need to be adjusted or discontinued in patients already receiving it. This medication should not be used in patients with end-stage renal disease or those on dialysis, as the effectiveness is unlikely to be realized. In patients with heart failure who are classified as mild to moderate (NYHA class I-II), it should be used with caution, and it is not recommended for those who are classified as severe (NYHA class III-IV). When this medication is used in conjunction with insulin or sulfonylureas, which stimulate insulin secretion, the risk of hypoglycemia may increase, necessitating dose adjustments. Potential side effects during the use of this medication include hypoglycemia, genital infections, increased urination, urinary tract infections, decreased fluid volume, and increased serum creatinine. Particularly, hypoglycemia may occur more frequently when combined with insulin or sulfonylureas, so caution should be exercised. Genital infections may occur more frequently in women and are mostly mild in nature. If urination becomes frequent, consult a doctor for any discomfort. This medication can rarely induce serious ketoacidosis; therefore, immediate medical attention should be sought if symptoms such as vomiting, abdominal pain, or difficulty breathing occur. Elderly patients and those at risk of fluid volume loss should be cautious of dehydration or hypotension, and the use of this medication can be temporarily suspended if necessary. This medication can cause serious urinary infections such as urosepsis and pyelonephritis, necessitating prompt treatment for any signs of infection. Pregnant or breastfeeding women should avoid the use of this medication, and if pregnancy is confirmed, it should be discontinued immediately. The safety and efficacy of this medication in children under 18 have not been established. No specific toxicity has been reported in the event of overdose, but appropriate treatment may be required depending on the clinical situation. This medication should be kept out of reach of children, and it is advisable to avoid transferring it to other containers. Caution is needed during driving or operating machinery due to the risk of hypoglycemia. Regular kidney function tests should be conducted during the course of this medication, and if any abnormal signs are noted, immediate consultation with medical personnel is necessary.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture, and it is best stored at a temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its efficacy for a longer period.
Pale yellow, biconvex, oval, film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
JW Pharmaceutical Corporation

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.